Clinical UpdatePrint this Activity for Offline ReferenceInstructions on Taking Medscape CME

Treatment of Cytomegalovirus (CMV) Retinitis in the Era of Highly Active Antiretroviral Therapy CME
Authors: James P. Dunn, MD; Daniel F. Martin, MD
Disclosures

Release Date: September 30, 2003; Valid for credit through September 30, 2004

This activity has expired.
CME in this activity indicates that it was developed according to ACCME guidelines and was certified for credit by one or more accredited CME or CE providers. Medscape cannot attest to the timeliness of expired CME activities.

Contents of This CME Activity
  1. Treatment of Cytomegalovirus (CMV) Retinitis in the Era of Highly Active Antiretroviral Therapy
    Abstract
    Introduction
    Epidemiology
    Pathogenesis
    Prophylaxis
    Screening
    Clinical Features of CMV Retinitis
    Differential Diagnosis
    Treatment
    Recurrent and Drug-Resistant CMV
    Impact of HAART on CMV Disease
    Discussion
    Review of Important Clinical Points
    References


 
Legal Disclaimer
The material presented here does not reflect the views of Medical Education Collaborative, Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity.
Copyright © 2003 Medscape.

 
Roche
  • This activity has expired.

    The accredited provider can no longer issue certificates for this activity. Medscape cannot attest to the timeliness of expired CME activities.

  • CME Information
All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.